PFE

Pfizer

Healthcare Drug Manufacturers - General NYSE

About the company

Pfizer, founded in 1849 by Charles Pfizer and Charles Erhart, has grown into a globally recognized powerhouse in the pharmaceutical industry. With a rich history spanning over 170 years, the company has consistently adapted to the changing landscape of healthcare and medical advancements. Pfizer's journey began with the production of chemicals and a diverse array of healthcare products. However, it strategically shifted its focus over time to become predominantly known for prescription drugs and vaccines. This strategic move has proven highly successful, especially in recent years as these segments now make up the majority of Pfizer's annual sales. Among Pfizer's top-selling products is the pneumococcal vaccine Prevnar 13. This vaccine has been instrumental in combatting pneumonia, a highly prevalent and dangerous respiratory infection, particularly in young children and the elderly. Prevnar 13 has demonstrated remarkable efficacy in preventing pneumonia caused by 13 strains of pneumococcus bacteria, making it a widely recommended vaccine across the globe. Another top-selling drug for Pfizer is Ibrance, a groundbreaking cancer medication that has revolutionized the treatment of hormone receptor-positive breast cancer. Ibrance, also known by its generic name palbociclib, is an oral therapy that specifically targets cancer cells to halt their growth. The drug has shown impressive results in clinical trials and has become a vital treatment option, providing hope for breast cancer patients. Pfizer's cardiovascular treatment, Eliquis, has also gained significant traction in the global market. Eliquis, developed in partnership with Bristol-Myers Squibb, is an anticoagulant that helps prevent blood clotting in patients with atrial fibrillation and other cardiovascular conditions. Its efficacy, coupled with its favorable safety profile, has made Eliquis an attractive option for physicians and patients alike. In the field of immunology, Pfizer's drug Xeljanz has made notable contributions. Xeljanz, or tofacitinib, is an oral therapy approved for the treatment of rheumatoid arthritis and psoriatic arthritis. By targeting specific molecules involved in the immune response, Xeljanz helps to alleviate symptoms and improve the quality of life for individuals living with these chronic autoimmune diseases. Pfizer's global reach is noteworthy, with international sales accounting for nearly 50% of the company's total sales. This global presence allows Pfizer to have a significant impact on healthcare worldwide. Emerging markets are an essential aspect of Pfizer's international sales, as the company recognizes the untapped potential and growing demand for pharmaceutical products in these regions. By focusing on emerging markets, which include countries like India, China, Brazil, and South Africa, Pfizer can not only expand its customer base but also address the healthcare needs of populations that have previously been underserved. These markets offer a unique opportunity for Pfizer to bring its life-saving medications and vaccines to individuals who may not have had access to such treatments previously. Pfizer's commitment to research and development is also a driving force behind its global success. The company invests heavily in discovering new therapies and advancing healthcare innovation. This dedication allows Pfizer to develop groundbreaking drugs and vaccines that can transform the lives of patients across the globe. Furthermore, Pfizer's commitment to corporate social responsibility is evident through its various initiatives. The company actively engages in philanthropic endeavors, supporting global health initiatives, as well as community-based programs that seek to improve access to healthcare and promote disease awareness. In conclusion, Pfizer's evolution into a pharmaceutical giant has been shaped by its strategic focus on prescription drugs and vaccines. With products like Prevnar 13, Ibrance, Eliquis, and Xeljanz leading the way, Pfizer has become a global leader in healthcare. The company's international sales, particularly in emerging markets, underscore its commitment to reaching diverse populations worldwide and improving global health outcomes. With its unwavering dedication to research and development, Pfizer continues to drive innovation and make a lasting impact on the lives of patients around the world.

Website: https://www.pfizer.com

Data updated: June 2, 2026

Sector comparison

We compare this company with the typical (middle) company in the same industry to show how it looks against similar businesses. This is information, not a recommendation.

Healthcare · 1346 peers in sector

Metric PFE Sector median Vs. industry
P/E 19.56 20.10 ↓ Below average
EPS 1.31 USD -1.14 USD ↑ Above average
Dividend yield 6.57% 0.00% ↑ Above average
Profit margin 11.83% 0.00% ↑ Above average
ROE 8.31% -58.84% ↑ Above average

Higher and lower here are only a comparison with the typical company in the industry — a higher or lower value on its own does not mean better or worse.

Financial statements & historical data

Income statements, balance sheets, cash flow, earnings and dividend history are available for registered users

Sign up for free

AI Summary

AI-generated company analysis is available for registered users.

Sign up for free

Where does this data come from?

Frequently Asked Questions

What is Pfizer?
Pfizer, founded in 1849 by Charles Pfizer and Charles Erhart, has grown into a globally recognized powerhouse in the pharmaceutical industry. With a rich history spanning over 170 years, the company has consistently adapted to the changing landscape of healthcare and medical advancements. Pfizer's journey began with the production of chemicals and a diverse array of healthcare products. However, it strategically shifted its focus over time to become predominantly known for prescription drugs and vaccines. This strategic move has proven highly successful, especially in recent years as these segments now make up the majority of Pfizer's annual sales. Among Pfizer's top-selling products is the pneumococcal vaccine Prevnar 13. This vaccine has been instrumental in combatting pneumonia, a highly prevalent and dangerous respiratory infection, particularly in young children and the elderly. Prevnar 13 has demonstrated remarkable efficacy in preventing pneumonia caused by 13 strains of pneumococcus bacteria, making it a widely recommended vaccine across the globe. Another top-selling drug for Pfizer is Ibrance, a groundbreaking cancer medication that has revolutionized the treatment of hormone receptor-positive breast cancer. Ibrance, also known by its generic name palbociclib, is an oral therapy that specifically targets cancer cells to halt their growth. The drug has shown impressive results in clinical trials and has become a vital treatment option, providing hope for breast cancer patients. Pfizer's cardiovascular treatment, Eliquis, has also gained significant traction in the global market. Eliquis, developed in partnership with Bristol-Myers Squibb, is an anticoagulant that helps prevent blood clotting in patients with atrial fibrillation and other cardiovascular conditions. Its efficacy, coupled with its favorable safety profile, has made Eliquis an attractive option for physicians and patients alike. In the field of immunology, Pfizer's drug Xeljanz has made notable contributions. Xeljanz, or tofacitinib, is an oral therapy approved for the treatment of rheumatoid arthritis and psoriatic arthritis. By targeting specific molecules involved in the immune response, Xeljanz helps to alleviate symptoms and improve the quality of life for individuals living with these chronic autoimmune diseases. Pfizer's global reach is noteworthy, with international sales accounting for nearly 50% of the company's total sales. This global presence allows Pfizer to have a significant impact on healthcare worldwide. Emerging markets are an essential aspect of Pfizer's international sales, as the company recognizes the untapped potential and growing demand for pharmaceutical products in these regions. By focusing on emerging markets, which include countries like India, China, Brazil, and South Africa, Pfizer can not only expand its customer base but also address the healthcare needs of populations that have previously been underserved. These markets offer a unique opportunity for Pfizer to bring its life-saving medications and vaccines to individuals who may not have had access to such treatments previously. Pfizer's commitment to research and development is also a driving force behind its global success. The company invests heavily in discovering new therapies and advancing healthcare innovation. This dedication allows Pfizer to develop groundbreaking drugs and vaccines that can transform the lives of patients across the globe. Furthermore, Pfizer's commitment to corporate social responsibility is evident through its various initiatives. The company actively engages in philanthropic endeavors, supporting global health initiatives, as well as community-based programs that seek to improve access to healthcare and promote disease awareness. In conclusion, Pfizer's evolution into a pharmaceutical giant has been shaped by its strategic focus on prescription drugs and vaccines. With products like Prevnar 13, Ibrance, Eliquis, and Xeljanz leading the way, Pfizer has become a global leader in healthcare. The company's international sales, particularly in emerging markets, underscore its commitment to reaching diverse populations worldwide and improving global health outcomes. With its unwavering dedication to research and development, Pfizer continues to drive innovation and make a lasting impact on the lives of patients around the world.
Are Pfizer shares expensive?
The price-to-earnings (P/E) ratio of Pfizer is 19.56 — the share price is 19.56 times the annual profit per share. That is lower than the typical company in the same industry (industry median: 20.10). This is information, not a recommendation. (as of 2026-06-02)
How big is Pfizer?
The market capitalization of Pfizer — the combined value of all its shares — is 146.08 B USD. The higher the market cap, the larger the company. (as of 2026-06-02)
Does Pfizer pay dividends?
The dividend yield of Pfizer is 6.57% — it shows the annual dividend relative to the share price. This is information, not a recommendation. (as of 2026-06-02)
What sector does Pfizer belong to?
Pfizer operates in the Healthcare sector, industry: Drug Manufacturers - General.

What do you gain?

With Ecrumen you gain full control over your investments and assets!

All your assets
Stock market investments, real estate, bonds. Be aware of what you have in your portfolio!
AI at the service of your investments
Analyze and optimize your investments using the latest technologies. Sentiments, analyses, tips, reports. Always with up-to-date data!
A community eager to help
Find a place with people similar to you. Share your opinions, see how others manage their investments. Get help with the problems that bother you!
What do you gain?

Want to stay up to date?

Subscribe to our newsletter to stay up to date with Ecrumena news and market information. No spam, unsubscribe in one click.

For more information, please refer to our terms of use.

0/120